Biotech IPO Market Opens, Venture’s Exit Window Opens Again
As the number of biotech IPOs recovered in 2024, a wave of unicorn companies that deferred going public during 2022-2023 is now imminent. This signals not merely a technical market rebound, but a revival of bold venture capital inflow into gene editing and advanced pharmaceutical manufacturing.
Biotech growth is dramatic. Gene-editing leader CRSP (CRISPR Therapeutics AG) closed at USD 51.42 as of October 30, 2026, with year-over-year revenue growth of 1,041.4%. Despite a market cap of USD 4.8 billion, net margin remained at 0%. Major player GILD (Gilead Sciences) at USD 170.68 (same date) with a market cap of USD 21.18 billion is far more stable, but its net margin remains in the red at -12.5%. BMRN (BioMarin Pharmaceutical) at USD 58.51 with a market cap of USD 1.12 billion shows relative soundness with revenue growth of 19.9% and a net margin of 2.1%.
Why Biotech Is Moving Now: Four Driving Factors
1. IPO Window Reopens: As the rate-hiking cycle ended and investor appetite for tech stocks recovered, the door for public offerings opened again. Pent-up funding demand from 2022-2023 is now being unleashed.
2. Venture Capital Exit Pressure: Early-stage venture funds had been waiting for exit opportunities from portfolio companies 10-15 years into their life. With IPOs resuming, that exit path has become clear.
3. Technology Advances and Favorable Regulatory Environment: CRSP’s 1,041.4% revenue growth suggests that gene-editing therapies are converting from clinical trials into actual regulatory approvals. Growing FDA approvals lift market confidence.
4. Incumbents Choosing IPO Over Acquisition: As established large players like GILD and BMRN raise assets in the public market rather than through M&A, the IPO path for new entrants becomes even clearer.
Why Biotech Still Matters: The Tightrope Between Growth and Risk
Strong Growth and Cutting-Edge Technology: CRSP’s 1,041.4% revenue growth rate means that a technological breakthrough—not a one-time event—is flowing into the market. Commercialization of gene-editing therapies is a long-term growth thesis.
Lack of Profitability and the Trap of High Valuation Multiples: CRSP saw revenue explode yet net margin remains at 0%. GILD carries a massive market cap with a -12.5% net margin. BMRN’s P/E of 157.1 shows how highly the market values future earnings, but that leaves room for disappointment.
Takeaway
Biotech IPO revival is evidence of technological progress and bold venture capital optimism. Yet the scale of losses at firms like CRSP and GILD, combined with their high valuations, means the market is pricing in a highly forward-looking view. Over the next 1-2 years, whether these companies actually achieve profitability will determine if this IPO wave is justified.
This article is for information only and is not investment advice.